168 related articles for article (PubMed ID: 34491016)
1. AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study.
Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Dayan S; Berg AK; Munavalli G
J Drugs Dermatol; 2021 Sep; 20(9):980-987. PubMed ID: 34491016
[TBL] [Abstract][Full Text] [Related]
2. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
[TBL] [Abstract][Full Text] [Related]
3. AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data.
Schlessinger J; Friedmann DP; Mayoral F; Mraz Robinson D; Glaser D; Wu D; Marcus K; Somenek M; Lin X
J Drugs Dermatol; 2021 Sep; 20(9):988-995. PubMed ID: 34491022
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.
Monheit GD; Baumann L; Maas C; Rand R; Down R
Dermatol Surg; 2020 Jan; 46(1):61-69. PubMed ID: 31356432
[TBL] [Abstract][Full Text] [Related]
6. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Baumann L; Brandt FS; Kane MA; Donofrio LM
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
[TBL] [Abstract][Full Text] [Related]
7. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
[TBL] [Abstract][Full Text] [Related]
9. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Rubin M; Dover J; Maas C; Nestor M
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
[TBL] [Abstract][Full Text] [Related]
10. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
Carruthers JD; Fagien S; Joseph JH; Humphrey SD; Biesman BS; Gallagher CJ; Liu Y; Rubio RG; ;
Plast Reconstr Surg; 2020 Jan; 145(1):45-58. PubMed ID: 31609882
[TBL] [Abstract][Full Text] [Related]
11. Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study.
Kestemont P; Hilton S; Andriopoulos B; Prygova I; Thompson C; Volteau M; Ascher B
Aesthet Surg J; 2022 Feb; 42(3):301-313. PubMed ID: 34472596
[TBL] [Abstract][Full Text] [Related]
12. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
J Drugs Dermatol; 2020 Oct; 19(10):985-991. PubMed ID: 33026771
[TBL] [Abstract][Full Text] [Related]
13. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
Carruthers A; Carruthers J; Said S
Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
[TBL] [Abstract][Full Text] [Related]
14. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
J Drugs Dermatol; 2021 Oct; 20(10):1052-1060. PubMed ID: 34636520
[TBL] [Abstract][Full Text] [Related]
15. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.
Ascher B; Rzany B; Kestemont P; Hilton S; Heckmann M; Bodokh I; Noah EM; Boineau D; Kerscher M; Volteau M; Le Berre P; Picaut P
Aesthet Surg J; 2020 Jan; 40(1):93-104. PubMed ID: 30893430
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.
Fischer T; Sattler G; Prager W; Rzany B; Pavicic T; Gauglitz G; Weissenberger P; Riaz S
J Drugs Dermatol; 2020 May; 19(5):461-469. PubMed ID: 32484631
[TBL] [Abstract][Full Text] [Related]
18. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
Kawashima M; Harii K; Horiuchi Y; Seidman E; Lei X; Hopfinger R; Lee E
Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
[TBL] [Abstract][Full Text] [Related]
19. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
